The National Pharmaceutical Pricing Authority (NPPA) has issued a Trade Margin Rationalisation (TMR) order capping margins on anti-cancer drugs, aiming to improve affordability. The move targets distribution inefficiencies but raises concerns about long-term sustainability and enforcement gaps.
NPPA Caps Trade Margins on Anti-Cancer Drugs
The National Pharmaceutical Pricing Authority (NPPA) has introduced a Trade Margin Rationalisation (TMR) framework to cap trade margins on select anti-cancer drugs, marking its latest intervention to control out-of-pocket expenditure on critical medicines. The order, effective immediately, applies to both patented and generic oncology products under the National List of Essential Medicines (NLEM), aiming to curb inflated retail pricing through regulated distribution margins.
The TMR model fixes trade margins as a percentage of the ex-factory price, with differential caps based on formulation type and supply chain complexity. The authority asserts that this will enhance price predictability and reduce instances of arbitrary mark-ups. However, critics argue that such measures act as temporary fixes—akin to 'taping a cracked pipe'—without addressing systemic issues like fragmented distribution, weak enforcement at the retail level, or lack of generic substitution at point-of-care.
Legal challenges are anticipated, particularly from industry stakeholders citing prior regulatory overreach claims. The order operates under the Drug Price Control Order (DPCO) 2013, exercising powers under Section 17 of the Essential Commodities Act, 1955. Practitioners should monitor subsequent notifications specifying drug-wise margins and compliance mechanisms. This policy shift may influence forthcoming pricing strategies for new oncology launches and biosimilars.
